التفاصيل البيبلوغرافية
| العنوان: |
The multichain interleukin-2 receptor: a target for immunotherapy. |
| المؤلفون: |
Waldmann, T A1 (AUTHOR), Pastan, I H (AUTHOR), Gansow, O A (AUTHOR), Junghans, R P (AUTHOR) |
| المصدر: |
Annals of Internal Medicine. 1/15/92, Vol. 116 Issue 2, p148-160. 13p. |
| مصطلحات موضوعية: |
*THERAPEUTIC use of monoclonal antibodies, *AUTOIMMUNE diseases, *BACTERIAL toxins, *CELL receptors, *GENETIC engineering, *MONOCLONAL antibodies, *RADIOIMMUNOIMAGING, *RADIOIMMUNOTHERAPY, *TOXINS, *TRANSFERASES, *T-cell lymphoma, *THERAPEUTICS, *CELL physiology |
| مستخلص: |
Activation of resting T-lymphocytes induces synthesis of interleukin-2 (IL-2) and expression of cell surface receptors for this lymphokine. In contrast to resting normal T-cells that do not express high-affinity IL-2 receptors (IL-2R), abnormal T-cells of patients with leukemia-lymphoma, certain autoimmune disorders, and individuals rejecting allografts express this receptor. Exploiting this difference in receptor expression, antibodies to the IL-2 receptor have been used effectively to treat patients with leukemia and lymphoma. One approach is to use monoclonal antibodies produced in mice; the disadvantage is that they are highly immunogenic. In an effort to reduce the immunogenicity of the mouse monoclonal antibodies, monoclonal-antibody-mediated therapy has been revolutionized by generating humanized antibodies produced by genetic engineering in which the molecule is human except for the antigen-combining regions, which are retained from the mouse. Further, to increase its cytotoxic effectiveness, the monoclonal antibody has been armed with toxins or radionuclides. Alternatively, IL-2 itself has been linked to a toxin to kill IL-2 receptor-bearing cells. Thus, IL-2 receptor-directed therapy provides a new method for treating certain neoplastic diseases and autoimmune disorders and for preventing allograft rejection. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
